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Histamine [2-(4-Imidazolyl)-ethylamine] modulates different biological processes, 
through histamine H1 and H2 receptors, and their respective blockers are widely used in 
treating allergic and gastric acid-related disorders. Histamine H1 and H2 receptor 
crossdesensitization and cointernalization induced by its agonists have been previously 
described. In this study, we show how this crosstalk determines the response to 
histamine H1 and H2 receptor inverse agonists and how histamine H1 and H2 receptor 
inverse agonists interfere with the other receptor’s response to agonists. By 
desensitization assays we demonstrate that histamine H1 and H2 receptor inverse 
agonists induce a crossregulation between both receptors. In this sense, the histamine H1 
receptor inverse agonists desensitize the cAMP response to amthamine, a histamine H2 
receptor agonist. In turn, histamine H2 receptor inverse agonists interfere with histamine 
H1 receptor signaling. We also determine that the crossdesensitization induced by 
histamine H1 or H2 receptor agonists alters the histamine inverse agonists receptor 
response: activation of histamine H1 receptor affects cAMP response induced by 
histamine H2 receptor inverse agonists, whereas histamine H2 receptor agonist induces a 
negative regulation on the anti-inflammatory response of histamine H1 receptor inverse 
agonists. Binding studies revealed that histamine H1 and H2 receptors cointernalize after 
stimulus with histamine receptor inverse agonists. In addition, the inhibition of the 
internalization process prevents receptor crossregulation. Our study provides new 
insights in the mechanisms of action of histamine H1 and H2 receptors that explain the 
effect of histamine H1 and H2 receptor inverse agonists and opens up new venues for 
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1. Introduction 
Histamine [2-(4-Imidazolyl)-ethylamine] is an important mediator of many 
physiological and pathological processes including inflammation, gastric acid secretion, 
neuromodulation, regulation of immune function, cell proliferation and differentiation, 
among others. Histamine exerts its biological effects by binding to four different G 
protein-coupled receptor subtypes (H1-H4) (Panula et al., 2015).  
Until now, the most clinically relevant uses of histamine receptor ligands are achieved 
through the interaction with histamine H1 or H2 receptors, which are widely expressed 
in many tissues. In this regard, histamine H1 receptor antagonists/inverse agonists are 
used in the treatment of several allergic conditions, such as rhinoconjunctivitis, 
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urticaria, and atopic dermatitis, and are promptly available as prescription and/or as 
over-the-counter drugs (Church, 2016). On the other hand, histamine H2 receptor 
antagonists/inverse agonists have proved to be active agents for the treatment of 
duodenal and gastric ulcers, reflux, esophagitis and Zollinger–Ellison syndrome 
(Hershcovici and Fass, 2011; Sigterman et al., 2013). Additionally, since histaminergic 
ligands are low-cost drugs with no patent protection, there is a great interest to facilitate 
the repurposing of these drugs for other pathologies. Consequently, a deep 
understanding of their mechanisms of action is needed. The histamine H1 and H2 
receptors are coexpressed in most human tissues and cell types, such as neurons, airway 
and vascular smooth muscle cells, endothelial cells, hepatocytes, epithelial cells, 
neutrophils, eosinophils, monocytes, dendritic cells, as well as T and B lymphocytes, 
among others (Jutel et al., 2009; Parsons and Ganellin, 2009). In most tissues, histamine 
H1 receptor couples to Gαq/11 leading to an increase in phosphoinositide metabolism, 
whereas histamine H2 receptor couples to Gαs, triggering adenylyl cyclase (A ) 
activation and cyclic AMP (cAMP) accumulation (Panula et al., 2015). In these 
systems, the action of endogenous histamine may result from the balance and 
coordination of the signaling events activated by these, or even more, subtypes of 
histamine receptors. In this way, previous studies of our laboratory have described the 
existence of histamine H1 and H2 receptor crossregulation. In native and recombinant 
systems, both receptors desensitize when cells are exposed to a sustained stimulus with 
histamine H1 or H2 receptor agonists. Interestingly, this crossdesensitization does not 
depend on second messengers nor their downstream kinases, PKA or PKC, but on G 
protein-coupled receptor kinase 2 (GRK2) (Alonso et al., 2013). In addition, upon 
activation of histamine H1 or H2 receptor, both cointernalize in endosomes and form 
heteromers. Since these crossregulation mechanisms proved to be critical for the output 
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response to histaminergic stimulation, it would be expected that it also affects the 
response of the histamine H1 and H2 receptor inverse agonists used in the clinic. 
Nowadays, it is accepted that ligands which have been classically described as inverse 
agonists, due to their negative efficacy at modulating the G protein pathway, could also 
display some positive efficacy regarding receptor desensitization, internalization, or 
even signaling though another pathway (Kenakin, 2002; Pupo et al., 2016). In this 
sense, our laboratory has described that several histamine H2 receptor inverse agonists 
behave as full agonists regarding histamine H2 receptor desensitization and 
internalization, in spite of diminishing cAMP production (Alonso et al., 2014, 2015). 
In the present work, we hypothesized that histamine H1 and H2 receptor inverse agonists 
also induce the crossdesensitization between histamine H1 and H2 receptors, and that the 
crossregulation induced by histamine H1 and H2 receptor agonists affects the behavior 
of histamine H1 and H2 receptor inverse agonists. In order to address this issue, we 
analyzed the receptor´s crossregulation in U937 cells, which endogenously express 
histamine H1 and H2 receptors and in cotransfected HEK293 cells. We utilise clinically 
relevant ligands as mepyramine, chlorpheniramine, triprolidine and diphenhydramine 
(first-generation histamine H1 receptor inverse agonists), cetirizine (second-generation 
histamine H1 inverse agonist) and the widely used histamine H2 receptor inverse 
agonists cimetidine, ranitidine and famotidine. 
2. Materials and Methods 
2.1. Materials  
Cell culture medium, antibiotics, isobutylmethyl xanthine (IBMX), cAMP, 
prostaglandin E2 (PGE2), 2,3-trifluormetilfenilhistamine dimaleate (histamine H1 
receptor agonist), bovine serum albumin (BSA), phorbol 12-myristate 13-acetate 
(PMA), lipopolysaccharides from Escherichia Coli (LPS), cimetidine, ranitidine 
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hydrochloride, famotidine, cetirizine dihydrocloride, chlorpheniramine maleate and 
diphenhydramine hydrochloride were obtained from Sigma Chemical Company (St. 
Louis, MO). Amthamine dihydrobromide, mepyramine maleate, triprolidine 







H]tiotidine, were purchased from 
Perkin Elmer Life Sciences (Boston, MA). Fetal bovine serum (FBS) was purchased 
from Natocor (Argentina). Other chemicals used were of analytical grade and obtained 
from standard sources.  
2.2. Cell culture and transfections  
U937 cells, DC6 and AD3 derived clones, were cultured at 37°C in a humidified 
atmosphere of 5% CO2 in RPMI 1640 medium, and HEK293 cells were cultured in 
Dulbecco´s modified Eagle´s medium (DMEM); all supplemented with 10% FBS and 
50 g/ml gentamicin. DC6 and AD3 cell lines were obtained by U937 stable 
transfection with pcDNA3-HA-dynaminK44A or pcDNA3-β1arrestin (319–418) 
respectively, and were previously characterized (Fernandez et al., 2008). U937 and 
HEK293 cells were purchased from ATCC. 
For transient transfection, HEK293 cells were grown to 80-90% confluency and the 
cDNA constructs were transfected using K2 Transfection System. The transfection 
protocol was optimized as recommended by the supplier (Biontex, Munich, Germany). 
Usually, assays were performed 48 h after transfection. The human histamine H1 
receptor (H1R) and histamine H2 receptor (H2R) were subcloned previously in our 
laboratory in pCEFL and pCEFLHA, respectively (Notcovich et al., 2010; Shayo et al., 
2001). 
2.3. cAMP assay 
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For desensitization assays, cells were pretreated with agonists, inverse agonists, and/or 
inhibitors at the times shown in the corresponding figure legends. Cells were then 
washed and resuspended in fresh medium containing 1 mM IBMX, incubated for 3 min, 
and exposed to 10 µM amthamine, 10 µM cimetidine, 10 µM ranitidine, 10 µM 
famotidine, or 1 µM PGE2 for 10 min to determine whether the system was able to 
generate cAMP. The reaction was stopped by ethanol addition followed by 
centrifugation at 2000 x g for 5 min. The ethanol phase was then dried and the residue 
resuspended in 50 mM Tris-HCl pH 7.4, 0.1% BSA. cAMP content was determined by 
competition of [
3
H]cAMP for PKA, as previously described (Davio et al., 1995). 
2.4. Reporter gene assay 
HEK293 cells seeded on 24-well plates were cotransfected with the pIL6-luciferase 
reporter plasmid, pCEFL-H1R and pCEFLHA-H2R. In some experiments, cells were 
cotransfected with the plasmid constructs indicated in the corresponding figure legend 
or an empty vector to maintain the total amount of DNA. After 6 h, cells were seeded in 
96-well plates, and after 24 h deprived from serum for another 16 h. Cells were then 
stimulated with the corresponding agents and luciferase activity was measured 6 h later 
with the Steady-Glo Luciferase Assay System according to the manufacturer's 
instructions (Promega Biosciences Inc. San Luis Obispo, CA, USA) using the GloMax 
96 Microplate Luminometer (Promega Biosciences Inc. San Luis Obispo, CA, USA). 
Experimental reporter activity was normalized to control activity. 
2.5. RT-PCR and quantitative real-time PCR 
Total RNA was isolated from U937 cells using Quick-Zol reagent (Kalium 
Technologies) following the manufacturer's instructions. For the first-strand cDNA 
synthesis, 2 μg of total RNA was reverse-transcribed using the High Capacity cDNA 
Reverse Transcription kit (AB) with random primers. Quantitative real-time PCR 
9 
 
(qPCR) was performed in triplicate using the resulting cDNA, the HOT FIREPol 
EvaGreen qPCR Mix Plus (Solis Biodyne) for product detection, and the following 
primers: COX-2 (cyclooxigenase-2) forward 5′-
TTCAAATGAGATTGTGGGAAAATTGCT-3′ and reverse 5′-
AGATCATCTCTGCCTGAGTATCTT-3′, human IL-8 (interleukin-8) forward 5´-
CTGCGCCAACACAGAAATTA-3´ and reverse 5´-ATTGCATCTGGCAACCCTAC-
3´ and human β-Actin (β-Act) forward, 5′ -GGACTTCGAGCAAGAGATGG-3′ and 
reverse 5′ -AGCACTGTGTTGGCGTACAG-3′. The cDNA was amplified by 45 cycles 
of denaturing (30 s at 95°C), annealing (30 s at 60°C), and extension (30 s at 72°C) 
steps. The specificity of each primer set was monitored by analyzing the dissociation 
curve, and the relative mRNA quantification was performed using the comparative 
ΔΔCt method using β-Actin as the housekeeping gene. 
2.6. Cell proliferation 
U937 cells were seeded at 1x10
5
 cells/ml in 24-wells plates, incubated for 24 h, 48 h or 
72 h with different combinations of compounds as indicated in the figure legend and 
then counted in a Neubauer chamber. 
2.7. Cell cycle analysis 
U937 cells growing in exponential phase were treated as indicated in the figure legend 
for 72 h. Then, cells were centrifuged at 1000 x g for 5 min, resuspended in one volume 
of phosphate buffered saline (PBS) and fixed and permeabilized by vigorous addition of 
nine volumes of ice-cold 70% (v/v) ethanol and stored at -20°C for a minimum of 24 h, 
prior to analysis. Cells at a density of approximately 1x10
6
 were resuspended in 0.1 ml 
staining solution [20 µg/ml propidium iodide (PI) and 100 µg/ml RNase A in PBS, pH 
7.4] and incubated in the dark at room temperature for 30 min. The percentage of cells 
in the sub-G0/G1, G0/G1, S, and G2/M cell cycle phases was determined by a FACS 
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Scan Flow Cytometer (Becton-Dickinson, Laguna Hills, CA). Data from at least three 
independent experiments were analyzed using FlowJo V10 program. 
2.8. Determination of phosphatidylserine exposure at the cell surface by annexin V 
binding assay 
U937 cells growing in exponential phase were treated with the corresponding 
compounds as indicated in the figure legend or 2% (v/v) dimethylsulfoxide (DMSO; 
positive control) for 72 h. Following cold PBS washing, 2x10
5
 cells were incubated 
with fluorescein isothiocyanate (FITC)-labeled annexin V and PI according to the 
manufacturer's instructions (Invitrogen) and analyzed using a FACS Scan Flow 
Cytometer (Becton-Dickinson). The different cell subpopulations were identified 
according to the annexin V/PI staining pattern, as follows: cells labeled with annexin V 
only were considered to be at an early apoptotic stage, cells labeled with annexin V and 
PI were considered to be at a late apoptotic stage, and cells labeled with PI only were 
considered necrotic.  
2.9. Radioligand binding assay 
Triplicate assays were performed in 50 mM Tris-HCl, pH 7.4. Saturation studies were 
performed by incubating 1x10
6
 U937 cells/tube or 1x10
4 
HEK293-H1R, HEK293-H2R 





H]mepyramine, in the absence or presence of 10 µM unlabeled 
tiotidine or mepyramine, respectively. Specific binding was calculated by subtraction of 
nonspecific binding from total binding. For HEK293 cells, the incubation was stopped 
by dilution with 3 ml of ice-cold 50 mM Tris-HCl, pH 7.4. For U937 cells, rapid 
filtration under reduced pressure onto Whatman GF/B glass-fiber filters, followed by 
three washes with 3 ml ice-cold buffer was performed. Experiments on intact cells were 
carried out at 4°C to avoid ligand internalization.  
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2.10. Statistical analysis 
Statistical analysis (from assays performed by triplicate from at least three independent 
experiments), binding data, sigmoidal dose-response, and desensitization fittings were 
performed with GraphPad Prism 6.00 for Windows, GraphPad Software (San Diego, 
CA). Statistical analysis was performed using one- or two-way ANOVA, followed by 
 unnett’s or Bonferroni´s multiple comparisons post test. Cell proliferation and cell 
cycle statistical analysis were carried out by one-way ANOVA followed by Tukey’s 




3.1. Histamine H1 receptor inverse agonists affect histamine H2 receptor response 
In order to evaluate the potential crossregulation between histamine H1 receptor inverse 
agonists and histamine H2 receptor response, we first analyzed the effect of cetirizine 
pretreatment on histamine H2 receptor response to amthamine (a potent and selective 
histamine H2 receptor agonist). In U937 cells pretreated with cetirizine, cAMP 
production following 10 μM amthamine stimuli decreased in a time- and concentration-
dependent manner (Fig. 1A and B). Maximal desensitization was attained after 30 min 
and with 10 μM cetirizine. Besides, preexposure of U937 cells to mepyramine, 
chlorpheniramine, triprolidine, or diphenhydramine (10 μM; 30 min) induced a 
significant desensitization of histamine H2 receptor in response to amthamine, whereas 
the response to PGE2 remained unaffected (Fig. 1C and D). The concentration used for 
amthamine and PGE2 corresponded to the maximum cAMP response in U937 cells 




To confirm that histamine H1 receptor inverse agonists desensitize histamine H2 
receptor response through histamine H1 receptor, we performed the same assay using 
HEK293 cells which only express histamine H2 receptor. As shown in Fig. 1E, no 
crossdesensitization occurs in the absence of histamine H1 receptor. As expected, when 
both receptors are coexpressed in HEK293 cells, pretreatment with histamine H1 
receptor inverse agonists also desensitized the histamine H2 receptor response to 
amthamine (Fig. 1F). 
These findings show that inverse agonists acting selectively through histamine H1 
receptor induce the crossdesensitization of histamine H2 receptor response, both in 
U937 native and HEK293 recombinant systems. 
3.2. Activation of histamine H2 receptor affects histamine H1 receptor ligands anti-
inflammatory response 
Our next question was whether the pharmacological action of histamine H1 receptor 
inverse agonists may be affected by the activation of histamine H2 receptor. Histamine, 
acting through histamine H1 receptor, plays a key role in the induction of early-phase 
allergic symptoms and inflammatory actions. Its activation upregulates the production 
and release of cytokines, chemokines and adhesion molecules by inflammatory cells, 
epithelium and endothelium (Asako et al., 1994; Kimura et al., 2004; Kordulewska et 
al., 2017; Matsubara et al., 2005; Yamauchi et al., 2007). It has also been reported that 
histamine promotes the induction of the proinflamamtory cytokine IL-6, through 
histamine H1 receptor in several systems (Cadman et al., 1994; Delneste et al., 1994; 
Kohda et al., 2002). In concordance, we observed that cetirizine, chlorpheniramine, 
triprolidine, or diphenhydramine significantly reduced the constitutive IL-6 promoter 
activity in transfected HEK293-H1R-H2R cells (Fig. 2A). Although it may seem that 
mepyramine reduced IL-6 promoter’s activity, no significant differences were observed 
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when compared to basal levels. Remarkably, cotreatment with the histamine H2 receptor 
agonist amthamine, prevented the decrease of IL-6 promoter´s activity induced by all of 
the histamine H1 receptor inverse agonists tested. When this assay was performed in 
HEK293 cells expressing only histamine H1 receptor, response to histamine H1 receptor 
inverse agonists was not modified by amthamine (Fig. 2B), indicating that amthamine 
achieves the interference by specifically binding to histamine H2 receptor. 
Next, we assessed if a histamine H2 receptor agonist is able to desensitize histamine H1 
receptor anti-inflammatory response in a cellular system of pathophysiological 
relevance. For this purpose, we differentiated U937 cells into macrophage-like cells 
with PMA and activated them with LPS. In order to evaluate the inflammatory 
response, IL-8 cytokine and COX-2 enzyme transcript levels were measured using 
quantitative real-time polymerase chain reaction. Histamine H1 receptor inverse 
agonists, mepyramine, cetirizine, chlorpheniramine, triprolidine, and diphenhydramine 
inhibited COX-2 and IL-8 gene expression. Interestingly, cotreatment with amthamine, 
significantly reverted the anti-inflammatory effect of histamine H1 receptor inverse 
agonists (Fig. 2C and D).  
3.3. Activation of histamine H1 receptor affects histamine H2 receptor response to 
inverse agonists 
Given the existence of a crossdesensitization between histamine H1 and H2 receptors 
induced by both agonists (Alonso et al., 2013) and that the stimulus with an histamine 
H2 receptor agonist affects the response to histamine H1 receptor inverse agonists, we 
evaluated whether histamine H1 receptor agonists could affect histamine H2 receptor 
response to inverse agonists in U937 cells. As expected, treatment with cimetidine, 
ranitidine and famotidine, classified as histamine H2 receptor inverse agonists, caused a 
reduction in cAMP levels (Fig. 3A). However, pretreatment with an histamine H1 
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receptor agonist (10 µM; 30 min) annulled the effect of histamine H2 receptor inverse 
agonists, indicating that histamine H1 receptor activation interferes with histamine H2 
receptor response to inverse agonists. We verified that pretreatment with the histamine 
H1 receptor agonist decreased histamine H2 receptor response to inverse agonists in 
cotransfected HEK293 cells expressing both receptors (Fig. 3B). Conversely, the 
reduction in cAMP levels induced by histamine H2 receptor inverse agonists was not 
modified in cells which only express histamine H2 receptor (Fig. 3C), showing the 
specificity of the histamine H1 receptor agonist effect. 
3.4. Histamine H2 receptor inverse agonists influence histamine H1 receptor response 
With the aim of establishing whether these ligands may interfere with histamine H1 
receptor response, we evaluated the effect of cimetidine, ranitidine, and famotidine on 
the histamine H1 receptor agonist-induced IL-6 promoter activity. The concentration 
used for histamine H1 receptor agonist corresponded to the maximum IL-6 promoter 
activity (data not shown). Treatment with all of the histamine H2 receptor inverse 
agonists assayed reduced the luciferase signal induced by stimulation with an histamine 
H1 receptor agonist in HEK293-H1R-H2R cells (Fig. 4A), while no interference was 
detected in HEK293-H1R cells (Fig. 4B). This interference was also observed when 
cells were pretreated with the histamine H2 receptor agonist amthamine (Fig. 4A), in a 
similar way to that previously described for inositol 1,4,5-trisphosphate response 
(Alonso et al., 2013).  
Consistently, in U937 cells differentiated with PMA, stimulation with an histamine H1 
receptor agonist induced gene expression of COX-2 and IL-8, and treatment with 
histamine H2 receptor inverse agonists annulled the pro-inflammatory response (Fig. 4C 
and D).  
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Taking in consideration that histamine H1 receptor activation mediates antiproliferative 
and apoptotic effects in U937 cells (Alonso et al., 2013), we analyzed the impact of 
histamine H2 receptor inverse agonists in the antiproliferative response to an histamine 
H1 receptor agonist. For this, U937 cells were incubated with an histamine H1 receptor 
agonist alone or in combination with cimetidine, ranitidine, or famotidine for 3 days and 
cell number, cell cycle stage and apoptosis were evaluated. The antiproliferative effect 
mediated by histamine H1 receptor was inhibited by treatment with histamine H2 
receptor inverse agonists (Fig. 5A and B). FACS studies showed that treatment with the 
histamine H1 receptor agonist induced an arrest in the cell cycle, evidenced by an 
increment in the SubG0 and a reduction in the S population compared to the control 
cells. Cotreatment with cimetidine, ranitidine or famotidine prevented this arrest, which 
was in accordance with the proliferative response observed (Fig. 5C). We also evaluated 
early and late apoptosis by PI and annexin V binding assays. Following U937 cells’ 
exposure to the histamine H1 receptor agonist, a reduction in viable cells with a 
concomitant increase in early and late apoptotic subpopulations was detected. This 
induction of apoptosis was blocked in the presence of all three histamine H2 receptor 
inverse agonists tested, cimetidine, ranitidine, or famotidine (Fig. 5D). 
Altogether, these results highlight the importance of the crossregulation between 
histamine H1 and H2 receptor in the final response to histaminergic ligands. 
3.5. Cointernalization of histamine H1 and H2 receptors is responsible for the 
crossregulation induced by inverse agonists 
In previous studies from our laboratory, we reported that histamine H1 and H2 receptors 
are cointernalized upon histamine H1 or H2 receptor agonist stimulation in U937, CHO 
and HEK293 cells (Alonso et al., 2013). In addition, treatment with histamine H2 
receptor inverse agonist leads to histamine H2 receptor internalization (Alonso et al., 
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2014). In order to evaluate a putative reciprocal internalization of histamine H1 and H2 





H]mepyramine binding sites after incubating U937 or 
transfected HEK293 cells with the ligands. Exposure to cetirizine (10 µM; 90 min) not 
only reduced the number of histamine H1 receptor binding sites in U937 cell membranes 
(58% respect to untreated cells), but also decreased the number of histamine H2 receptor 
membrane sites (65% respect to untreated cells) (Fig. 6A). In the same way, treatment 
with ranitidine and famotidine (10 µM; 90 min) internalized histamine H1 receptor by 
43% and 31%, respectively (Fig. 6B). With the intention of evaluating the histamine H2 
receptor-binding specificity of the ligands necessary to induce cointernalization, 
saturation binding assays with [
3
H]mepyramine were performed in transfected 
HEK293-H1R-H2R and HEK293-H1R cells exposed to ranitidine and famotidine. 
HEK293-H1R-H2R cells showed similar results to those obtained with U937 cells; 
where ranitidine and famotidine led to a 29% and 32% decrease in histamine H1 
receptor binding sites, respectively (Fig. 6C). On the other hand, ranitidine and 
famotidine failed to stimulate histamine H1 receptor internalization in HEK293-H1R 
cells, although cetirizine, the histamine H1 receptor ligand, internalized histamine H1 
receptor by 45% (Fig. 6D).  
These findings reveal that inverse agonists induce receptor cointernalization as part of 
the crosstalk between histamine H1 and H2 receptors. 
In an attempt to determine if the cointernalization of histamine H1 and H2 receptors 
induced by inverse agonists is responsible for the crossregulation process or if an 
additional mechanism triggers it, we blocked the internalization of the receptors and 
evaluated their crossregulation. Given that arrestin and dynamin proved to be essential 
for the internalization of several GPCRs including histamine receptors (Fernandez et al., 
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2008; Wolfe and Trejo, 2007), we pharmacologically or genetically inhibited arrestin 
and dynamin and assessed the effect on histamine H1 and H2 receptor crossregulation. 
First, we evaluated the response to amthamine after cetirizine, chlorpheniramine and 
triprolidine pretreatment in the presence of dynasore, a dynamin inhibitor, in U937 
cells. None of the histamine H1 receptor inverse agonists was able to impair histamine 
H2 receptor agonist response in the presence of dynasore (Fig. 7A), which efficiently 
inhibited histamine H1 receptor internalization (supplementary Fig. 1). Similar results 
were observed in U937 derived clones DC6 and AD3, obtained by stable transfection 
with a dynamin or arrestin dominant negative mutant respectively; cetirizine, 
chlorpheniramine, and triprolidine did not induce histamine H2 receptor 
crossdesensitization (Fig. 7B). Next, the effect of dynasore on the crossdesensitization 
induced by histamine H2 receptor inverse agonists on histamine H1 receptor response 
was evaluated in HEK293T-H1R-H2R cells. Figure 7C shows that neither, cimetidine, 
ranitidine nor famotidine were able to reduce IL-6 promoter´s activity induced by the 
histamine H1 receptor agonist when internalization was blocked.  
Altogether, these results indicate that the inhibition of the internalization process 
prevents the receptor’s crossdesensitization, and thus the cointernalization induced by 




The major findings of the present study are that: 1) the response to inverse agonists may 
be crossregulated by the activation of either histamine H1 or H2 receptors, 2) histamine 
H1 and H2 receptor inverse agonists crossdesensitize the receptor´s response to their 
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agonist, and 3) the crointernalization of histamine H1 and H2 receptors is responsible for 
the crossdesensitization induced by inverse agonists. 
One hundred and thirty-four GPCRs are targets for drugs approved in the United States 
and European Union and it is estimated that approximately 35% of approved drugs 
target GPCRs. Among the receptors with the highest number of approved drugs are the 
histamine H1 and H2 receptors (Sriram and Insel, 2018). Many of the histamine H1 and 
H2 receptor antagonists, now reclassified as inverse agonists, have been successfully 
used in the clinic, achieving the desired effects, although side effects do happen. The 
concept of inverse agonism arose from experimental observations showing that certain 
drugs were able to reduce the activity of receptor systems that were active even in the 
absence of agonists. These ligands bind preferentially and stabilize the inactive 
conformation of the receptors. However, whether inverse agonism is essential or 
important for these drugs to exert their medicinal actions has not been clarified yet.  
From the moment these drugs were implemented to date, several concepts have 
changed, including GPCR crossregulation and pluridimensional efficacy of GPCR 
ligands, which allow researchers to continue elucidating new aspects of these drugs´ 
mechanisms of action.  
It has been described that GPCRs functionally interact with other pathways in several 
ways. In particular, histamine H1 and H2 receptor agonists interfere with the agonist´s 
response of the other GPCR. This crossregulation has already been described in 
recombinant and naïve systems involving GRK2-dependent crossdesensitization and 
cointernalization/ heterodimerization of both receptors, and has proven to be part of 
histamine´s fine regulation to achieve a final response (Alonso et al., 2013). Now, we 
show that the crossdesensitization induced by histamine H1 or H2 receptor agonists also 
influences the response to inverse agonists. In this way, the activation of whichever of 
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these receptors modifies the response of histamine H1 or H2 receptor inverse agonists in 
different systems. Thus, the anti-inflammatory effect of histamine H1 receptor inverse 
agonists evaluated by the reduction in IL-8 and COX-2 gene expression in monocytic 
U937 cells was less pronounced when histamine H2 receptor was activated by 
amthamine (Fig. 2C and D). On the other hand, cAMP response triggered by incubation 
with the histamine H2 receptor inverse agonist was prevented when U937 cells were 
pretreated with the histamine H1 receptor agonist (Fig. 3A). These results evidence how 
the efficacy of these inverse agonists is affected by the presence and activation of the 
other subtype of histaminergic receptor. This crosstalk may explain why histamine H1 
and H2 receptor inverse agonists have different efficacies in different tissues. Therefore, 
when considering targeting histamine H1 or H2 receptors, it would be necessary to take 
into account not only the selectivity, affinity and residence time of ligands, but also the 
expression levels of both receptors and their crossregulation in order to accomplish the 
desired effect.  
It is important to note that histamine H1 and H2 receptors are coupled to different G 
proteins and that their crossinterference induced by histamine H1 and H2 receptor 
inverse agonists depends on the cointernalization mechanism. To date, histamine H1 and 
H2 receptor inverse agonist have shown to interfere with the response of other GPCRs 
that share the same signaling pathway. In fact, treatment with these drugs stabilizes a 
conformation of the receptor that, although it is inactive, it may couple and recruit G-
protein making it less available for other unrelated receptors that signal through the 
same pathway (Monczor et al., 2003; Tubio et al., 2010).  
Our results show that interference may occur among receptors that do not share the 
same signaling pathway and determine cell’s fate. Thus, the exposure to histamine H1 
receptor agonist, alone or in combination with specific histamine H2 receptor inverse 
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agonists, ultimately determines whether U937 cells arrest their cell cycle and engage 
with apoptotic processes or proliferate instead (Fig. 5).  
It is important to mention that the IC50 of cetirizine needed to achieve histamine H2 
receptor desensitization was 0.43 µM or 170 ng/ml (Fig. 1B), becoming clinically 
relevant since pharmacokinetic studies after oral administration of the clinically used 
dose (10 mg/day) reported a maximal plasma concentration of 311 ng/ml. Among all 
the tested histamine H1 receptor inverse agonist, cetirizine showed the highest efficacy 
leaving a residual activity of histamine H2 receptor between 40% and 60% for HEK293-
H1R-H2R and U937 cells, respectively (Fig.1C and F). This interference in histamine H2 
receptor response was similar to that achieved by histamine H1 receptor agonist 
(Alonso et al., 2013), denoting a control of the histamine response through histamine H2 
receptor by histamine H1 receptor.  
Several GPCRs regulate their functions through cointernalization, which explains the 
signaling crossdesensitization reported in somatostatin 2A/opioid receptors and 
adenosine A2A/dopamine D2 receptors (Hillion et al., 2002; Pfeiffer et al., 2002), and 
can even trigger new intracellular signaling pathways. In this sense, Smith et al. 
described that the cointernalization of the protease-activated receptor-4/purinergic 
receptor P2Y12 heterodimer is necessary for β-arrestin recruitment to endosomes and 
Akt signaling (Smith et al., 2017). Regarding histamine H1 and H2 receptors, 
cointernalization and heterodimerization have been described upon histamine H1 or H2 
receptor agonist stimulus, although receptor cointernalization is not the only mechanism 
of desensitization (Alonso et al., 2013). In reference to histamine H2 receptor inverse 
agonists, cimetidine, ranitidine, and famotidine have shown to elicit histamine H2 
receptor internalization as part of their pluripotential efficacy, in an arrestin and 
dynamin dependent manner (Alonso et al., 2014). This report provides the first evidence 
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that histamine H1 receptor inverse agonists can induce the internalization of their own 
receptor. In line with these findings, cetirizine showed to induce histamine H1 receptor 
internalization both, in cells that endogenously express the receptor (U937) and in a 
recombinant system (HEK293T-H1R and HEK293T-H1R-H2R) (Fig. 6). Moreover, 
regarding the crossregulation between histamine H1 and H2 receptor, here we describe a 
new efficacy for several histamine H1 and H2 receptor inverse agonists, as they induce 
the cointernalization of both receptors, interfering in the signaling cascade of receptors 
that have never been challenged to their own ligands. Further investigations are 
necessary in order to unravel what happens after internalization, whether the receptors 
heterodimerize in the endosomes and may, eventually, trigger some type of intracellular 
signaling. Our findings open an interesting field of study related to histamine H1 and H2 
receptor inverse agonists. 
The repurposing of well-characterized and well-tolerated drugs in order to treat illnesses 
for which they were not originally intended has emerged as an attractive alternative to a 
long and costly process of drug development. Repositioning antihistaminergic ligands 
seems a promising idea given that histamine exerts a variety of actions throughout the 
body and that histamine H1 and H2 receptors are ubiquitously expressed. In this sense, 
novel clinical applications for histamine H1 receptor antagonists/inverse agonists are 
currently being studied for the management of different pathological situations, such as 
inflammatory-related conditions (in combination with glucocorticoids) (Zappia et al., 
2015), analgesia (Stein et al., 2016) or neurodegenerative and sleep disorders (Kim and 
Song, 2017; Krystal, 2015). In the same way, evidence for anti-cancer effects of the 
histamine H2 receptor inverse agonist cimetidine has been reported in various types of 
neoplasias, including glioblastoma, cholangiocarcinoma, malignant melanoma, renal 
cell carcinoma, colorectal and gastric cancer (Dana et al., 2017; Pantziarka et al., 2014). 
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Likewise, histamine H2 receptor antagonist/inverse agonist use was recently associated 
with a lower risk for incident heart failure and better preserved stroke volume, left 
ventricular end-diastolic volume, and mass/volume ratio over time in community 
dwelling adults (Leary et al., 2016). It would be interesting to determine whether 
beneficial effects of histamine H2 receptor antagonists/inverse agonists in heart failure 
pathologies rely, at least partially, on histamine H1 and H2 receptor 
crossdesensitization/cointernalization. Thus, histamine H2 receptor antagonists/inverse 
agonists could also modulate the histamine H1 receptor-mediated pro-inflammatory 
response to endogenous histamine, aiding the resolution of the cardiac disease. We 
believe that these newly described pharmacological behaviors may encourage and 
clarify the mechanisms of histamine H2 receptor antagonists/inverse agonists in cardiac 
tissue.  
This crosstalk may be responsible for the beneficial effects of histamine H2 receptor 
inverse agonists on heart pathologies and may also explain unwanted effects of these 
drugs on other tissues. In this way, Allen et al. reported an anaphylactoid reaction 
following cessation of high-dose ranitidine in a 19-year-old female with mast cell 
activation syndrome, hypermobile Ehlers-Danlos syndrome and postural tachycardia 
syndrome (Allen et al., 2018). The authors suggest that patients who take ranitidine, 
after withdrawal, can suffer an exacerbated effect of histamine caused by upregulation 
of histamine H2 receptor and raised histamine levels due to histidine decarboxylase 
induction, which is in concordance with previous in vitro studies (Alonso et al., 2015; 
Monczor and Fernandez, 2016; Smit et al., 1996). Considering our present results, it is 
feasible that in the same way that sustained internalization of histamine H2 receptor led 
to upregulation on histamine H2 receptor levels, sustained cointernalization of histamine 
H1 receptor by ranitidine treatment may also lead to upregulation of histamine H1 
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receptor, which may explain the observed anaphylactoid reaction after cessation of 
ranitidine treatment. 
In conclusion, our findings support the notion that the crosstalk between histamine H1 
and H2 receptor signaling is not restrictive to agonist ligands and, as a result, may have 
profound consequences regarding treatment with histamine H1 and H2 receptor 
antagonists/inverse agonists. Receptor agonists crossregulate receptor inverse agonists 
response and receptor inverse agonists crossregulate histamine response. Considering 
the large number of cell types in different tissues that express histamine H1 and H2 
receptors, the clinically widespread use of antagonists/inverse agonists acting through 
both receptors in the treatment of several human diseases, and the advantage of drug 
repositioning, the accurate characterization of ligands´ mechanisms of action should 
allow us to reinterpret side effects of drugs and/or to ascribe new uses. 
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Figure Legends:  
Figure 1. Effect of histamine H1 receptor inverse agonists on histamine H2 receptor 
response. (A) U937 cells were incubated with 10 µM cetirizine at different time points 
and washed with PBS. cAMP response to 10 µM amthamine was determined as detailed 
in Materials and Methods. (B) U937 cells were incubated with different concentrations 
of cetirizine (CET) for 30 min, washed with PBS, and cAMP response to 10 µM 
amthamine was determined. (C-D) U937 cells were exposed to 10 µM mepyramine 
(MEP), chlorpheniramine (CHLOR), triprolidine (TRIP), or diphenhydramine (DIPH) 
for 30 min, washed with PBS, and cAMP response to 10 µM amthamine (C) or 10 µM 
PGE2 (D) was determined. (E-F) HEK293-H2R (E) or HEK293-H1R-H2R cells (F) were 
exposed to 10 µM histamine H1 receptor inverse agonists for 30 min, washed with PBS, 
and cAMP response to 10 µM amthamine was determined. 100% corresponds to 
amthamine response without pretreatment (control). Data represent mean ± S.E.M. (n = 
3). ns. not significant; **P < 0.01; ***P < 0.001 respect to control.  
 
Figure 2. Effect of histamine H2 receptor agonist on histamine H1 receptor inverse 
agonists response. HEK293 cells cotransfected with IL-6-Luc, H1R and H2R (A) or IL-
6-Luc and H1R coding constructs (B), were incubated for 10 min with 10 µM 
amthamine (grey bars) or not (white bars), and then treated with 10 µM mepyramine 
(MEP), cetirizine (CET), chlorpheniramine (CHLOR), triprolidine (TRIP), or 
diphenhydramine (DIPH) for 6 h. Luciferase activity was determined as detailed in 
Materials and Methods. 100% correspond to basal activity without histamine H2 
receptor agonist treatment (control). Data represent mean ± S.E.M. (n = 3). ns. not 
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significant, *P < 0.05; **P < 0.01; ***P < 0.001 respect to control. 
##
 P < 0.01; 
###
P < 
0.001. (C-D) U937 cells incubated for 24 h with 100 nM PMA were exposed for 10 min 
with 10 µM amthamine (grey bars) or not (white bars), treated with 10 µM mepyramine 
(MEP), cetirizine (CET), chlorpheniramine (CHLOR), triprolidine (TRIP), or 
diphenhydramine (DIPH) for 18 h and stimulated with 1 µg/ml LPS for 4 h. COX-2 (C) 
and IL-8 (D) mRNA levels were quantified by qPCR as detailed in Materials and 
Methods. Data represent mean ± S.E.M. (n = 3). ns. not significant, *P < 0.05; **P < 
0.01; ***P < 0.001 respect to control. 
#
P < 0.05; 
##
P < 0.01; 
###
P < 0.001. 
 
Figure 3. Effect of histamine H1 receptor agonist on histamine H2 receptor inverse 
agonists response. (A) U937, (B) HEK293-H1R-H2R, or (C) HEK293-H2R cells were 
exposed to 10 µM H1 agonist for 30 min (grey bars) or not (white bars), washed with 
PBS, and cAMP response to 10 µM cimetidine (CIM), ranitidine (RAN) or famotidine 
(FAM) was determined as indicated in Materials and Methods. Data represent mean ± 
S.E.M. (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001 respect to basal levels without 
histamine H1 receptor agonist pretreatment. ns. not significant;
 #
P < 0.05; 
##
P < 0.01; 
###
P < 0.001 respect to basal levels after histamine H1 receptor agonist pretreatment.  
 
Figure 4. Effect of histamine H2 receptor inverse agonists on histamine H1 receptor 
response. (A-B) HEK293 cells cotransfected with IL-6-Luc, H1R and H2R (A) or IL-6-
Luc and H1R coding constructs (B), were incubated for 10 min with 10 µM cimetidine 
(CIM), ranitidine (RAN), famotidine (FAM) or amthamine (histamine H2 receptor 
agonist), and then treated with 10 µM histamine H1 receptor agonist (grey bars) or not 
(white bars) for 6 h. Luciferase activity was determined as detailed in Materials and 
Methods. Data represent mean ± S.E.M. (n = 3). ns. not significant; 
###
P < 0.001 respect 
32 
 
to H1 agonist response. 
***
P < 0.001. (C-D) U937 cells incubated for 24 h with 100 nM 
PMA were exposed for 10 min with 10 µM cimetidine (CIM), ranitidine (RAN) or 
famotidine (FAM), and then treated with 10 µM histamine H1 receptor agonist for 18 h. 
COX-2 and IL-8 mRNA levels were quantified by qPCR as detailed in Materials and 
Methods. Data represent mean ± S.E.M. (n = 3). 
###
P < 0.001 respect to histamine H1 
receptor agonist response, ***P < 0.001.  
 
Figure 5. Effect of histamine H2 receptor inverse agonists on the inhibition of cell 
proliferation and apoptosis induced by histamine H1 receptor agonist. U937 cells 
were treated with 10 µM histamine H1 receptor agonist, alone or in combination with 10 
µM cimetidine (CIM), ranitidine (RAN) or famotidine (FAM) for 24, 48 and 72 h (A) or 
72 h (B–D). After treatment, cell proliferation (A and B), cell cycle stage (C) and 
phosphatidylserine exposure at the cell surface by annexin V binding (D) were 
evaluated as detailed in Materials and Methods. (A) Data were calculated as the means 
± S.D. of assay triplicates. Similar results were obtained in at least three independent 
experiments. (B) Data represent mean ± S.E.M. (n = 3). ***P < 0.001 respect to control 
cells. 
###
P < 0.001 respect to histamine H1 receptor agonist response. (C) Data represent 
mean ± S.E.M. (n = 3). **P < 0.01 respect to control cells. (D). Data represent mean ± 
S.E.M. (n = 3). ***P < 0.001 respect to control cells. 
 
Figure 6. Cointernalization of histamine H1 and H2 receptors induced by histamine 





assays were performed in U937 cells  control (●) or treated for 90 min with 10 µM 
cetirizine ( ET) (■). (B) [
3
H]Mepyramine saturation assays were performed in U937 
cells  control (●) or treated for 90 min with 10 µM ranitidine (RAN) (□) or 10 µM 
33 
 
famotidine (FAM) (○). ( -D) [
3
H]Mepyramine saturation assays were performed in 
HEK293-H1R-H2R (C) or HEK293-H1R ( ) cells  control (●) or treated for 90 min with 
10 µM cetirizine ( ET) (■), 10 µM ranitidine (RAN) (□) or 10 µM famotidine (FAM) 
(○).  ata were calculated as the mean ± S.D. of assay triplicates. Similar results were 
obtained in at least three independent experiments. Right (A-D): Data represent the 
percentage Bmax value fitted by nonlinear regression of the saturation assay, calculated 
as the means ± S.E.M. (n = 3). 100% corresponds to untreated cells (control). ***P < 
0.001; **P < 0.01 respect to control cells. 
 
Figure 7. Receptor internalization is involved in the crossdesensitization induced 
by histamine H1 and H2 receptor inverse agonists. (A) U937 cells pretreated for 30 
min with 80 µM dynasore (grey bars) or not (white bars), were exposed for 30 min to 
10 µM cetirizine (CET), chlorpheniramine (CHLOR), or triprolidine (TRIP) washed 
with PBS, and cAMP response to 10 µM amthamine was determined. (B) U937, AD3 
and DC6 cells were exposed for 30 min to different 10 µM histamine H1 receptor 
inverse agonists as indicated in the figure, washed with PBS, and cAMP response to 10 
µM amthamine was determined. Data represent mean ± S.E.M. (n = 3). ***P < 0.001 
respect to histamine H2 receptor agonist response without pretreatment. ns. not 
significant. (C) HEK293 cells cotransfected with IL-6-Luc, H1R and H2R coding 
constructs, were pretreated for 30 min with 80 µM dynasore (Dyn) (grey bars) or not 
(white bars), exposed for 10 min to 10 µM cimetidine (CIM), ranitidine (RAN) or 
famotidine (FAM), and then treated with 10 µM histamine H1 receptor agonist for 6 h. 
Luciferase activity was determined as detailed in Materials and Methods. Data represent 
mean ± S.E.M. (n = 3). ns. not significant; 
#
P < 0.05; 
##
P < 0.01; 
###
P < 0.001 respect to 
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